IOP-lowering effect of ONO-9054, a novel dual agonist of prostanoid EP3 and FP receptors, in monkeys

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 4, 2015, Pages 2547-2552

  Yamane, Shinsaku ^a   Karakawa, Tomohiro ^a   Nakayama, Satoshi ^a   Nagai, Kazufumi ^a   Moriyuki, Kazumi ^a   Neki, Shinichi ^a   Suto, Fumitaka ^a   Kambe, Tohru ^a   Hirota, Yasushi ^a   Kawabata, Kazuhito ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

EP3; FP; Intraocular pressure; Prostaglandin; Prostanoid receptor

Indexed keywords

LATANOPROST; ONO 9054; ONO AG 367; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN D2; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN FP RECEPTOR; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; THROMBOXANE A2 RECEPTOR; TRAVOPROST; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; EYE DROPS; PROSTAGLANDIN F; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN F2ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONJUNCTIVA; CORNEA OPACITY; DRUG SAFETY; EC50; FEMALE; HAPLORHINI; HISTOPATHOLOGY; IC50; INTRAOCULAR PRESSURE; IRIS; MALE; MYDRIASIS; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR AFFINITY; SCORING SYSTEM; SINGLE DRUG DOSE; AGONISTS; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; FOLLOW UP; MACACA FASCICULARIS; METABOLISM; OCULAR HYPOTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DINOPROST; DISEASE MODELS, ANIMAL; FOLLOW-UP STUDIES; INTRAOCULAR PRESSURE; MACACA FASCICULARIS; OCULAR HYPOTENSION; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, PROSTAGLANDIN; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE;

EID: 84939633379     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-16181     Document Type: Article

References (24)

1. Friedman DS, Wolfs RC, O’Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122:532-538.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
3. Sit AJ, Liu JH. Pathophysiology of glaucoma and continuous measurements of intraocular pressure. Mol Cell Biomech. 2009;6:57-69.
4. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965-1972.
5. Ota T, Aihara M, Saeki T, Narumiya S, Araie M. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci. 2006;47: 3395-3399.
6. Schlotzer-Schrehardt U, Zenkel M, Nusing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002;43: 1475-1487.
7. Flach AJ, Eliason JA. Topical prostaglandin E2 effects on normal human intraocular pressure. J Ocul Pharmacol. 1988; 4:13-18.
8. Bito LZ, Camras CB, Gum GG, Resul B. The ocular hypotensive effects and side effects of prostaglandins on the eyes of experimental animals. In: Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York, NY: Alan R. Liss Inc.; 1989:349-368.
9. Kay JH, Colandra JC. Interpretation eye irritation tests. J Soc Cosmet Chem. 1962;13:281-289.
10. Crowston JG, Lindsey JD, Morris CA, Wheeler L, Medeiros FA, Weinreb RN. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Invest Ophthalmol Vis Sci. 2005;46:4571-4577.
11. Crowston JG, Lindsey JD, Aihara M, Weinreb RN. Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor. Invest Ophthalmol Vis Sci. 2004; 45:3555-3559.
12. Sharif NA. Synthetic FP-prostaglandin-induced contraction of rat uterus smooth muscle in vitro. Prostaglandins Leukot Essent Fatty Acids. 2008;78:199-207.
13. Li N, Chen X, Zhou Y, Wei M, Yao X. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol. 2006;34:755-764.
14. Cheng JW, Cai JP, Li Y, Wei RL. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angleclosure glaucoma. J Glaucoma. 2009;18:652-657.
15. Orme M, Collins S, Dakin H, Kelly S, Loftus J. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary openangle glaucoma and ocular hypertension. Curr Med Res Opin. 2010;26:511-528.
16. Gabelt BT, Hennes EA, Bendel MA, Constant CE, Okka M, Kaufman PL. Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009;25:1-8.
17. Schlotzer-Schrehardt U, Zenkel M, Nusing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002;43: 1475-1487.
18. Gabelt BT, Hennes EA, Bendel MA, Constant CE, Okka M, Kaufman PL. Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009;25:1-8.
19. Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochem Biophys Acta. 2000;1483:285-293.
20. Waterbury LD, Eglen RM, Faurot GF, Cooper GF. EP3, but not EP2, FP, or TP prostanoid-receptor stimulation may reduce intraocular pressure. Invest Ophthalmol Vis Sci. 1990;31: 2560-2567.
21. Hasegawa H, Negishi M, Ichikawa A. Two isoforms of the prostaglandin E receptor EP3 subtype different in agonistindependent constitutive activity. J Biol Chem. 1996;271: 1857-1860.
22. Negishi M, Hasegawa H, Ichikawa A. Prostaglandin E receptor EP3 gamma isoform, with mostly full constitutive Gi activity and agonist-dependent Gs activity. FEBS Lett. 1996;386:165-168.
23. Jin J, Mao GF, Ashby B. Constitutive activity of human prostaglandin E receptor EP3 isoforms. Br J Pharmacol. 1997;121:317-323.
24. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 2007;282:11613-11617.